Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Deals
|
M&A
|
Financials
|
Strategy
|
Lifecycle Management
|
Legal
|
Business
EVENTS
Today
Berlin, Germany
Today
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
Pharming asks for share dilution in cash hunt
16 March 2010
Pharming 's shares have fallen by 12% on news that the Dutch firm is planning a share issue. The company will hold an extraordinary general meeting (EGM) where it will ask shareholders to approve plans to raise more cash. Pharming ended 2009 with around €2.3 million in cash and marketable securities (net of bank overdrafts) and in January it boosted its cash position after agreeing a €7.5 million debt financing. However, the firm now needs to raise more cash at the risk of diluting current ...
 
Ipsen grants Rhythm licence to non-core metabolic programmes UPDATE
16 March 2010
Ipsen has granted Rhythm Pharmaceuticals an exclusive worldwide licence for the development and commercialisation of its melanocortin and ghrelin programmes. The early preclinical peptide compounds in the programmes target obesity, metabolic diseases and gastrointestinal disorders. Ipsen said the ...
Ipsen grants Rhythm licence to non-core metabolic programmes
15 March 2010
Ipsen has granted Rhythm Pharmaceuticals an exclusive worldwide licence for the development and commercialisation of its melanocortin and ghrelin programmes. The early preclinical peptide compounds in the programmes target obesity, metabolic diseases and gastrointestinal disorders. Ipsen said the ...
 
OSI eyes third party options after board rejects Astellas bid
16 March 2010
OSI Pharmaceuticals ' board has unanimously rejected Astellas 's unsolicited $52 per share cash offer for the company, recommending that OSI shareholders do the same. After a formal review, which included external advisors, the board's conclusion was that "the offer does not fully reflect OSI's ...
Abbott to acquire Facet for $450 million
10 March 2010
Abbott has succeeded where Biogen Idec failed last year in having a takeover offer accepted by Facet Biotech . Abbott will pay $27 per share for Facet, which values the biotech at $722 million minus its cash and marketable securities of $272 million. Facet's president and CEO Faheem ...
 
OSI eyes third party options after board rejects Astellas bid
16 March 2010
OSI Pharmaceuticals ' board has unanimously rejected Astellas 's unsolicited $52 per share cash offer for the company, recommending that OSI shareholders do the same. After a formal review, which included external advisors, the board's conclusion was that "the offer does not fully reflect OSI's ...
AstraZeneca fluffs its lines on emerging markets
16 March 2010
AstraZeneca has hastily rewritten expectations for its business in emerging markets, an area of key growth if it is to prosper after several key products lose patent protection in its core markets. In little over a month, the UK firm has scaled back the anticipated boon to its business of sales ...
 
Emerging markets to make up 48% of pharma growth, IMS Health says
16 March 2010
IMS Health is predicting that emerging markets will expand by $90 billion during 2009-13, contributing 48% of annual pharmaceutical market growth in 2013, a jump from 37% in 2009. This comes at time when many multinational pharma firms are looking to these markets –with their rising GDPs, ...
AstraZeneca fluffs its lines on emerging markets
16 March 2010
AstraZeneca has hastily rewritten expectations for its business in emerging markets, an area of key growth if it is to prosper after several key products lose patent protection in its core markets. In little over a month, the UK firm has scaled back the anticipated boon to its business of sales ...
 
Merck/Portola's betrixaban shows bleeding benefit in Phase IIb
16 March 2010
Merck / Portola Pharmaceuticals ' investigational Factor Xa inhibiting anticoagulant betrixaban was associated with significantly less clinically relevant bleeding than warfarin when given at 40mg/day to patients with atrial fibrillation, show new results from a dose-finding study presented on ...
Counterfeiters beware: WHO shows poor countries how to procure antimalarials
10 March 2010
Establishments that produce substandard or counterfeit antimalarials will find it harder to sell their products to developing countries after the World Health Organization published new guidelines this week spelling out how to buy quality-made artemisinin-based combination therapies (ACTs), the ...
 
KV unit Ethex pleads guilty to two felonies in oversize pill case
09 March 2010
KV Pharmaceutical unit Ethex Corp pled guilty on March 2nd in the US District Court for the Eastern District of Missouri to two felonies in connection with the manufacturing of oversized prescription drug tablets, according to the US Justice Department. The government charged that, despite having ...
AstraZeneca awaits decision in US Crestor patent case
08 March 2010
AstraZeneca has a lot riding on the outcome of US patent litigation relating to its cholesterol therapy, Crestor (rosuvastatin). It failed last December in its attempt to gain summary judgement on allegations of inequitable conduct in the obtainment of the active ingredient patent ('314), and as a ...
 

Executive Briefing – Health technology assessment: a brief look at the EU
31 December 2009

Global demographic developments are forcing countries to scrutinise their healthcare sectors and ...

 Market Insight - Fear gives way to prudence a...
 How to run clinical trials in the Middle East...

2010 Scrip 100 - Scrip PharmaMetrics
09 December 2009

Deals speak volumes about company sentiment and the overall health of the pharmaceutical industry. ...

2010 Scrip 100 - Can Piramal do a 'Nano' for Indian pharma?
09 December 2009

The launch of a new small car has shown the world that India can innovate. The couple in charge of ...

European Medicines Agency and logos: snakes, DNA and the pestle and mortar
22 December 2009
Elizabeth Sukkar
Logos are said to be an important part of an organisation's branding. Really good logos contribute ...

Face-to-face with Abingworth's Stephen Bunting:we've had time to adapt to tough markets
25 August 2009
Sukaina Virji
While many venture capital (VC) firms have dropped beneath the radar during the current credit ...

Your Career in Pharma
26 September 2008
The choosy candidate, Can translational medicine deliver? and MHRA in the frame

Scrip's Stock Tracker February 2010
12 March 2010
Ashley Yeo
Talk of dividends being under threat at companies such as Bristol-Myers Squibb , Pfizer and Lilly , ...

© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm